|
- Drugs (psychoactive) - World Health Organization (WHO)
The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important
- Alcohol, Drugs and Addictive Behaviours
The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours
- WHO Drug Information
About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers
- Expert Committee on Drug Dependence (ECDD)
Expert Committee on Drug Dependence ECDD is a scientific advisory body to WHO that consists of an independent group of experts in the field of drugs and medicines and drug dependence liability
- Defined Daily Dose (DDD) - World Health Organization (WHO)
Drug consumption can be expressed in cost, number of units, number of prescriptions or by the physical quantity of drugs However these variables can vary between regions and countries over time This limits comparisons of drug consumption at an international level To address this, a technical unit of measurement, the Defined Daily Dose (DDD) was created
- Antifungal agents in clinical and preclinical development: overview and . . .
This report presents the first World Health Organization (WHO) analysis of antifungal agents in preclinical and clinical development It covers systemic antifungal drugs in development worldwide, including label extension and repurposed products, and critically evaluates how well the current pipeline addresses infections caused by WHO fungal priority pathogens
- Long-acting injectable lenacapavir proves effective in HIV prevention . . .
The full results of the PURPOSE 1 trial, presented at the 25th International AIDS Conference, demonstrate the safety and efficacy of the long-acting injectable antiretroviral drug lenacapavir (LEN) for PrEP in HIV-negative cisgender women LEN is a HIV-1 capsid inhibitor that is delivered by subcutaneous injection twice a year for HIV prevention
- Improving prevention and treatment for drug use disorders
The use of psychoactive drugs and psychotropic substances without medical supervision is associated with significant health risks and can lead to the development of drug use disorders Untreated drug use disorders increase risks of morbidity and mortality for individuals, trigger substantial costs to society including lost productivity, increased health care expenditure, and costs related to
|
|
|